

## 117TH CONGRESS 2D SESSION

## S. 3834

To strengthen medical device supply chains.

## IN THE SENATE OF THE UNITED STATES

March 14, 2022

Mr. Braun (for himself and Mr. Marshall) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions

## A BILL

To strengthen medical device supply chains.

1	Be it enacted by the Senate and House of Representa-
2	tives of the United States of America in Congress assembled,
3	SECTION 1. STRENGTHENING MEDICAL DEVICE SUPPLY
4	CHAINS.
5	(a) In General.—Section 506J of the Federal
6	Food, Drug, and Cosmetic Act (21 U.S.C. 356j) is amend-
7	ed—
8	(1) in the flush text at the end of subsection
9	(a)—
10	(A) by inserting "or of any other cir-
11	cumstance that is likely to lead to a meaningful

- disruption in the supply of the device or a shortage of the device, and there is no other available device that could reasonably be substituted for that device in the United States' before the period; and
  - (B) by adding at the end the following:

    "The Secretary shall develop and publish a list
    of device product codes required to comply with
    this subsection, and update the list every 3
    years, or in response to a public health emergency.";
  - (2) by redesignating subsections (h) and (i) as subsections (j) and (k), respectively;
- 14 (3) by inserting after subsection (g) the fol-15 lowing:
- "(h) RISK MANAGEMENT PLANS.—Each manufacturer of a device that is included on the list described in subsection (a), shall develop, maintain, and, as appropriate, implement a risk management plan that identifies and evaluates risks to the supply of the device, as applicable, for each establishment in which such device is manufactured. A risk management plan under this subsection—
  - "(1) may identify and evaluate risks to the supply of more than one device, or device category, manufactured at the same establishment; and

6

7

8

9

10

11

12

13

23

24

25

1	"(2) shall be subject to inspection and copying
2	by the Secretary pursuant to section 704 or at the
3	request of the Secretary.";
4	(4) in subsection (f), by inserting "or (i)" after
5	"subsection (a)"; and
6	(5) by inserting after subsection (h), as added
7	by paragraph (3), the following:
8	"(i) Additional Notifications.—The Secretary
9	may receive voluntary notifications from a manufacturer
10	of a device that is life-supporting, life-sustaining, or in-
11	tended for use in emergency medical care or during sur-
12	gery, or any other device the Secretary determines to be
13	critical to the public health, pertaining to a permanent dis-
14	continuance in the manufacture of the device (except for
15	any discontinuance as a result of an approved modification
16	of the device) or an interruption of the manufacture of
17	the device that is likely to lead to a meaningful disruption
18	in the supply of that device in the United States, and the
19	reasons for such discontinuance or interruption."; and
20	(6) in subsection (j) (as so redesignated by
21	paragraph (2))—
22	(A) by striking "shall be construed to af-
23	fect" and inserting the following: "shall be con-
24	strued—
25	"(1) to affect";

1	(B) by striking the period at the end and
2	inserting "; or"; and
3	(C) by adding at the end the following:
4	"(2) to grant the Secretary the authority to—
5	"(A) require specific design, management,
6	implementation, or updating of risk manage-
7	ment plans;
8	"(B) assess performance or compliance
9	with a risk management plan, under subsection
10	(h); or
11	"(C) require notification under subsection
12	(i).''.
13	(b) REPORT.—Not later than 2 years after the date
14	of enactment of this Act, and annually thereafter, the Sec-
15	retary of Health and Human Services shall prepare and
16	submit to the Committee on Health, Education, Labor,
17	and Pensions of the Senate and the Committee on Energy
18	and Commerce of the House of Representatives a report
19	on the use of information manufacturers submit pursuant
20	to section 506J of the Federal Food, Drug, and Cosmetic
21	Act (21 U.S.C. 356j) and applicable guidance issued with
22	respect to such section, and any actions taken by the Sec-
23	retary to mitigate or prevent a device shortage.
24	(e) Guidance on Voluntary Notifications of
25	DISCONTINUANCE OR INTERRUPTION OF DEVICE MANU-

- 1 FACTURE.—Not later than 1 year after the date of enact-
- 2 ment of this Act, the Secretary shall issue draft guidance
- 3 to facilitate voluntary notifications under subsection (i) of
- 4 section 506J of the Federal Food, Drug, and Cosmetic
- 5 Act (21 U.S.C. 356j), as added by subsection (a). Such
- 6 guidance shall include a description of circumstances in
- 7 which a voluntary notification under such subsection (i)
- 8 may be appropriate, recommended timeframes within
- 9 which sponsors may submit such a notification, the proc-
- 10 ess for receiving such notifications, and actions the Sec-
- 11 retary may take to mitigate or prevent a shortage result-
- 12 ing from a discontinuance or interruption in the manufac-
- 13 ture of a device for which such notification is received.
- 14 The Secretary shall issue final guidance not later than 1
- 15 year after the close of the comment period for the draft

16 guidance.

 $\bigcirc$